Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 11/2012

Open Access 01-11-2012 | Original article

The simultaneous ex vivo detection of low-frequency antigen-specific CD4+ and CD8+ T-cell responses using overlapping peptide pools

Authors: Satwinder Kaur Singh, Maaike Meyering, Tamara H. Ramwadhdoebe, Linda F. M. Stynenbosch, Anke Redeker, Peter J. K. Kuppen, Cornelis J. M. Melief, Marij J. P. Welters, Sjoerd H. van der Burg

Published in: Cancer Immunology, Immunotherapy | Issue 11/2012

Login to get access

Abstract

The ability to measure antigen-specific T cells at the single-cell level by intracellular cytokine staining (ICS) is a promising immunomonitoring tool and is extensively applied in the evaluation of immunotherapy of cancer. The protocols used to detect antigen-specific CD8+ T-cell responses generally work for the detection of antigen-specific T cells in samples that have undergone at least one round of in vitro pre-stimulation. Application of a common protocol but now using long peptides as antigens was not suitable to simultaneously detect antigen-specific CD8+ and CD4+ T cells directly ex vivo in cryopreserved samples. CD8 T-cell reactivity to monocytes pulsed with long peptides as antigens ranged between 5 and 25 % of that observed against monocytes pulsed with a direct HLA class I fitting minimal CTL peptide epitope. Therefore, we adapted our ICS protocol and show that the use of tenfold higher concentration of long peptides to load APC, the use of IFN-α and poly(I:C) to promote antigen processing and improve T-cell stimulation, does allow for the ex vivo detection of low-frequency antigen-specific CD8+ and CD4+ T cells in an HLA-independent setting. While most of the improvements were related to increasing the ability to measure CD8+ T-cell reactivity following stimulation with long peptides to at least 50 % of the response detected when using a minimal peptide epitope, the final analysis of blood samples from vaccinated patients successfully showed that the adapted ICS protocol also increases the ability to ex vivo detect low-frequency p53-specific CD4+ T-cell responses in cryopreserved PBMC samples.
Appendix
Available only for authorised users
Literature
1.
go back to reference Cerundolo V (1999) T cells work together to fight cancer. Curr Biol (CB) 9(18):R695–R697CrossRef Cerundolo V (1999) T cells work together to fight cancer. Curr Biol (CB) 9(18):R695–R697CrossRef
2.
go back to reference Melief CJ, Van Der Burg SH, Toes RE, Ossendorp F, Offringa R (2002) Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. Immunol Rev 188:177–182PubMedCrossRef Melief CJ, Van Der Burg SH, Toes RE, Ossendorp F, Offringa R (2002) Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. Immunol Rev 188:177–182PubMedCrossRef
3.
go back to reference Toes RE, Ossendorp F, Offringa R, Melief CJ (1999) CD4 T cells and their role in antitumor immune responses. J Exp Med 189(5):753–756PubMedCrossRef Toes RE, Ossendorp F, Offringa R, Melief CJ (1999) CD4 T cells and their role in antitumor immune responses. J Exp Med 189(5):753–756PubMedCrossRef
5.
go back to reference Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey SG, Smith FO, Klapper J, Morton K, Laurencot C, White DE, Rosenberg SA (2008) Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol Off J Am Soc Clin Oncol 26(32):5233–5239. doi:10.1200/JCO.2008.16.5449 CrossRef Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey SG, Smith FO, Klapper J, Morton K, Laurencot C, White DE, Rosenberg SA (2008) Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol Off J Am Soc Clin Oncol 26(32):5233–5239. doi:10.​1200/​JCO.​2008.​16.​5449 CrossRef
6.
go back to reference Verdegaal EM, Visser M, Ramwadhdoebe TH, van der Minne CE, van Steijn JA, Kapiteijn E, Haanen JB, van der Burg SH, Nortier JW, Osanto S (2011) Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha. Cancer Immunol Immunother (CII) 60(7):953–963. doi:10.1007/s00262-011-1004-8 CrossRef Verdegaal EM, Visser M, Ramwadhdoebe TH, van der Minne CE, van Steijn JA, Kapiteijn E, Haanen JB, van der Burg SH, Nortier JW, Osanto S (2011) Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha. Cancer Immunol Immunother (CII) 60(7):953–963. doi:10.​1007/​s00262-011-1004-8 CrossRef
7.
go back to reference Daayana S, Elkord E, Winters U, Pawlita M, Roden R, Stern PL, Kitchener HC (2010) Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. Br J Cancer 102(7):1129–1136. doi:10.1038/sj.bjc.6605611 PubMedCrossRef Daayana S, Elkord E, Winters U, Pawlita M, Roden R, Stern PL, Kitchener HC (2010) Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. Br J Cancer 102(7):1129–1136. doi:10.​1038/​sj.​bjc.​6605611 PubMedCrossRef
8.
go back to reference Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Essahsah F, Fathers LM, Offringa R, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, van der Burg SH, Melief CJ (2009) Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 361(19):1838–1847. doi:10.1056/NEJMoa0810097 PubMedCrossRef Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Essahsah F, Fathers LM, Offringa R, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, van der Burg SH, Melief CJ (2009) Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 361(19):1838–1847. doi:10.​1056/​NEJMoa0810097 PubMedCrossRef
9.
go back to reference van Poelgeest MI, van Seters M, van Beurden M, Kwappenberg KM, Heijmans-Antonissen C, Drijfhout JW, Melief CJ, Kenter GG, Helmerhorst TJ, Offringa R, van der Burg SH (2005) Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment. Clin Cancer Res Off J Am Assoc Cancer Res 11(14):5273–5280. doi:10.1158/1078-0432.CCR-05-0616 CrossRef van Poelgeest MI, van Seters M, van Beurden M, Kwappenberg KM, Heijmans-Antonissen C, Drijfhout JW, Melief CJ, Kenter GG, Helmerhorst TJ, Offringa R, van der Burg SH (2005) Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment. Clin Cancer Res Off J Am Assoc Cancer Res 11(14):5273–5280. doi:10.​1158/​1078-0432.​CCR-05-0616 CrossRef
10.
go back to reference Welters MJ, Kenter GG, de Vos van Steenwijk PJ, Lowik MJ, Berends-van der Meer DM, Essahsah F, Stynenbosch LF, Vloon AP, Ramwadhdoebe TH, Piersma SJ, van der Hulst JM, Valentijn AR, Fathers LM, Drijfhout JW, Franken KL, Oostendorp J, Fleuren GJ, Melief CJ, van der Burg SH (2010) Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci USA 107(26):11895–11899. doi:10.1073/pnas.1006500107 PubMedCrossRef Welters MJ, Kenter GG, de Vos van Steenwijk PJ, Lowik MJ, Berends-van der Meer DM, Essahsah F, Stynenbosch LF, Vloon AP, Ramwadhdoebe TH, Piersma SJ, van der Hulst JM, Valentijn AR, Fathers LM, Drijfhout JW, Franken KL, Oostendorp J, Fleuren GJ, Melief CJ, van der Burg SH (2010) Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci USA 107(26):11895–11899. doi:10.​1073/​pnas.​1006500107 PubMedCrossRef
11.
go back to reference Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Lowik MJ, Berends-van der Meer DM, Drijfhout JW, Valentijn AR, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, Melief CJ, van der Burg SH (2008) Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res Off J Am Assoc Cancer Res 14(1):178–187. doi:10.1158/1078-0432.CCR-07-1880 CrossRef Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Lowik MJ, Berends-van der Meer DM, Drijfhout JW, Valentijn AR, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, Melief CJ, van der Burg SH (2008) Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res Off J Am Assoc Cancer Res 14(1):178–187. doi:10.​1158/​1078-0432.​CCR-07-1880 CrossRef
12.
go back to reference Betts MR, Ambrozak DR, Douek DC, Bonhoeffer S, Brenchley JM, Casazza JP, Koup RA, Picker LJ (2001) Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. J Virol 75(24):11983–11991. doi:10.1128/JVI.75.24.11983-11991.2001 PubMedCrossRef Betts MR, Ambrozak DR, Douek DC, Bonhoeffer S, Brenchley JM, Casazza JP, Koup RA, Picker LJ (2001) Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. J Virol 75(24):11983–11991. doi:10.​1128/​JVI.​75.​24.​11983-11991.​2001 PubMedCrossRef
13.
go back to reference Tobery TW, Wang S, Wang XM, Neeper MP, Jansen KU, McClements WL, Caulfield MJ (2001) A simple and efficient method for the monitoring of antigen-specific T cell responses using peptide pool arrays in a modified ELISpot assay. J Immunol Methods 254(1–2):59–66PubMedCrossRef Tobery TW, Wang S, Wang XM, Neeper MP, Jansen KU, McClements WL, Caulfield MJ (2001) A simple and efficient method for the monitoring of antigen-specific T cell responses using peptide pool arrays in a modified ELISpot assay. J Immunol Methods 254(1–2):59–66PubMedCrossRef
14.
go back to reference Karlsson AC, Martin JN, Younger SR, Bredt BM, Epling L, Ronquillo R, Varma A, Deeks SG, McCune JM, Nixon DF, Sinclair E (2003) Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells. J Immunol Methods 283(1–2):141–153PubMedCrossRef Karlsson AC, Martin JN, Younger SR, Bredt BM, Epling L, Ronquillo R, Varma A, Deeks SG, McCune JM, Nixon DF, Sinclair E (2003) Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells. J Immunol Methods 283(1–2):141–153PubMedCrossRef
16.
go back to reference de Jong A, van der Hulst JM, Kenter GG, Drijfhout JW, Franken KL, Vermeij P, Offringa R, van der Burg SH, Melief CJ (2005) Rapid enrichment of human papillomavirus (HPV)-specific polyclonal T cell populations for adoptive immunotherapy of cervical cancer. Int J Cancer (Journal international du cancer) 114(2):274–282. doi:10.1002/ijc.20721 de Jong A, van der Hulst JM, Kenter GG, Drijfhout JW, Franken KL, Vermeij P, Offringa R, van der Burg SH, Melief CJ (2005) Rapid enrichment of human papillomavirus (HPV)-specific polyclonal T cell populations for adoptive immunotherapy of cervical cancer. Int J Cancer (Journal international du cancer) 114(2):274–282. doi:10.​1002/​ijc.​20721
17.
go back to reference Janetzki S, Panageas KS, Ben-Porat L, Boyer J, Britten CM, Clay TM, Kalos M, Maecker HT, Romero P, Yuan J, Kast WM, Hoos A, Elispot Proficiency Panel of the CVCIAWG (2008) Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother (CII) 57(3):303–315. doi:10.1007/s00262-007-0380-6 CrossRef Janetzki S, Panageas KS, Ben-Porat L, Boyer J, Britten CM, Clay TM, Kalos M, Maecker HT, Romero P, Yuan J, Kast WM, Hoos A, Elispot Proficiency Panel of the CVCIAWG (2008) Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother (CII) 57(3):303–315. doi:10.​1007/​s00262-007-0380-6 CrossRef
18.
go back to reference Moodie Z, Price L, Gouttefangeas C, Mander A, Janetzki S, Lower M, Welters MJ, Ottensmeier C, van der Burg SH, Britten CM (2010) Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immunother (CII) 59(10):1489–1501. doi:10.1007/s00262-010-0875-4 CrossRef Moodie Z, Price L, Gouttefangeas C, Mander A, Janetzki S, Lower M, Welters MJ, Ottensmeier C, van der Burg SH, Britten CM (2010) Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immunother (CII) 59(10):1489–1501. doi:10.​1007/​s00262-010-0875-4 CrossRef
19.
go back to reference van der Burg SH, Ressing ME, Kwappenberg KM, de Jong A, Straathof K, de Jong J, Geluk A, van Meijgaarden KE, Franken KL, Ottenhoff TH, Fleuren GJ, Kenter G, Melief CJ, Offringa R (2001) Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes. Int J Cancer (Journal international du cancer) 91(5):612–618 van der Burg SH, Ressing ME, Kwappenberg KM, de Jong A, Straathof K, de Jong J, Geluk A, van Meijgaarden KE, Franken KL, Ottenhoff TH, Fleuren GJ, Kenter G, Melief CJ, Offringa R (2001) Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes. Int J Cancer (Journal international du cancer) 91(5):612–618
20.
go back to reference Welters MJ, de Jong A, van den Eeden SJ, van der Hulst JM, Kwappenberg KM, Hassane S, Franken KL, Drijfhout JW, Fleuren GJ, Kenter G, Melief CJ, Offringa R, van der Burg SH (2003) Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. Cancer Res 63(3):636–641PubMed Welters MJ, de Jong A, van den Eeden SJ, van der Hulst JM, Kwappenberg KM, Hassane S, Franken KL, Drijfhout JW, Fleuren GJ, Kenter G, Melief CJ, Offringa R, van der Burg SH (2003) Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. Cancer Res 63(3):636–641PubMed
21.
go back to reference Britten CM, Janetzki S, van der Burg SH, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJ, O’Donnell-Tormey J, Odunsi K, Old LJ, Pawelec G, Roep BO, Romero P, Hoos A, Davis MM (2011) Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond. Cancer Immunol Immunother (CII) 60(1):15–22. doi:10.1007/s00262-010-0940-z CrossRef Britten CM, Janetzki S, van der Burg SH, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJ, O’Donnell-Tormey J, Odunsi K, Old LJ, Pawelec G, Roep BO, Romero P, Hoos A, Davis MM (2011) Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond. Cancer Immunol Immunother (CII) 60(1):15–22. doi:10.​1007/​s00262-010-0940-z CrossRef
23.
go back to reference van der Burg SH, Kwappenberg KM, Geluk A, van der Kruk M, Pontesilli O, Hovenkamp E, Franken KL, van Meijgaarden KE, Drijfhout JW, Ottenhoff TH, Melief CJ, Offringa R (1999) Identification of a conserved universal Th epitope in HIV-1 reverse transcriptase that is processed and presented to HIV-specific CD4+ T cells by at least four unrelated HLA-DR molecules. J Immunol 162(1):152–160PubMed van der Burg SH, Kwappenberg KM, Geluk A, van der Kruk M, Pontesilli O, Hovenkamp E, Franken KL, van Meijgaarden KE, Drijfhout JW, Ottenhoff TH, Melief CJ, Offringa R (1999) Identification of a conserved universal Th epitope in HIV-1 reverse transcriptase that is processed and presented to HIV-specific CD4+ T cells by at least four unrelated HLA-DR molecules. J Immunol 162(1):152–160PubMed
24.
go back to reference Britten CM, Gouttefangeas C, Welters MJ, Pawelec G, Koch S, Ottensmeier C, Mander A, Walter S, Paschen A, Muller-Berghaus J, Haas I, Mackensen A, Kollgaard T, Thor Straten P, Schmitt M, Giannopoulos K, Maier R, Veelken H, Bertinetti C, Konur A, Huber C, Stevanovic S, Wolfel T, van der Burg SH (2008) The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunol Immunother (CII) 57(3):289–302. doi:10.1007/s00262-007-0378-0 CrossRef Britten CM, Gouttefangeas C, Welters MJ, Pawelec G, Koch S, Ottensmeier C, Mander A, Walter S, Paschen A, Muller-Berghaus J, Haas I, Mackensen A, Kollgaard T, Thor Straten P, Schmitt M, Giannopoulos K, Maier R, Veelken H, Bertinetti C, Konur A, Huber C, Stevanovic S, Wolfel T, van der Burg SH (2008) The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunol Immunother (CII) 57(3):289–302. doi:10.​1007/​s00262-007-0378-0 CrossRef
25.
go back to reference Lattanzi L, Rozera C, Marescotti D, D’Agostino G, Santodonato L, Cellini S, Belardelli F, Gavioli R, Ferrantini M (2011) IFN-alpha boosts epitope cross-presentation by dendritic cells via modulation of proteasome activity. Immunobiology 216(5):537–547. doi:10.1016/j.imbio.2010.10.003 PubMedCrossRef Lattanzi L, Rozera C, Marescotti D, D’Agostino G, Santodonato L, Cellini S, Belardelli F, Gavioli R, Ferrantini M (2011) IFN-alpha boosts epitope cross-presentation by dendritic cells via modulation of proteasome activity. Immunobiology 216(5):537–547. doi:10.​1016/​j.​imbio.​2010.​10.​003 PubMedCrossRef
27.
go back to reference Sikora AG, Jaffarzad N, Hailemichael Y, Gelbard A, Stonier SW, Schluns KS, Frasca L, Lou Y, Liu C, Andersson HA, Hwu P, Overwijk WW (2009) IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity. J Immunol 182(12):7398–7407. doi:10.4049/jimmunol.0802982 PubMedCrossRef Sikora AG, Jaffarzad N, Hailemichael Y, Gelbard A, Stonier SW, Schluns KS, Frasca L, Lou Y, Liu C, Andersson HA, Hwu P, Overwijk WW (2009) IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity. J Immunol 182(12):7398–7407. doi:10.​4049/​jimmunol.​0802982 PubMedCrossRef
28.
go back to reference de Vos van Steenwijk PJ, Heusinkveld M, Ramwadhdoebe TH, Lowik MJ, van der Hulst JM, Goedemans R, Piersma SJ, Kenter GG, van der Burg SH (2010) An unexpectedly large polyclonal repertoire of HPV-specific T cells is poised for action in patients with cervical cancer. Cancer Res 70(7):2707–2717. doi:10.1158/0008-5472.CAN-09-4299 CrossRef de Vos van Steenwijk PJ, Heusinkveld M, Ramwadhdoebe TH, Lowik MJ, van der Hulst JM, Goedemans R, Piersma SJ, Kenter GG, van der Burg SH (2010) An unexpectedly large polyclonal repertoire of HPV-specific T cells is poised for action in patients with cervical cancer. Cancer Res 70(7):2707–2717. doi:10.​1158/​0008-5472.​CAN-09-4299 CrossRef
30.
go back to reference Reiser M, Wieland A, Plachter B, Mertens T, Greiner J, Schirmbeck R (2011) The immunodominant CD8 T cell response to the human cytomegalovirus tegument phosphoprotein pp 65(495–503) epitope critically depends on CD4 T cell help in vaccinated HLA-A*0201 transgenic mice. J Immunol 187(5):2172–2180. doi:10.4049/jimmunol.1002512 PubMedCrossRef Reiser M, Wieland A, Plachter B, Mertens T, Greiner J, Schirmbeck R (2011) The immunodominant CD8 T cell response to the human cytomegalovirus tegument phosphoprotein pp 65(495–503) epitope critically depends on CD4 T cell help in vaccinated HLA-A*0201 transgenic mice. J Immunol 187(5):2172–2180. doi:10.​4049/​jimmunol.​1002512 PubMedCrossRef
31.
go back to reference Speetjens FM, Kuppen PJ, Welters MJ, Essahsah F, Voet van den Brink AM, Lantrua MG, Valentijn AR, Oostendorp J, Fathers LM, Nijman HW, Drijfhout JW, van de Velde CJ, Melief CJ, van der Burg SH (2009) Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin Cancer Res Off J Am Assoc Cancer Res 15(3):1086–1095. doi:10.1158/1078-0432.CCR-08-2227 CrossRef Speetjens FM, Kuppen PJ, Welters MJ, Essahsah F, Voet van den Brink AM, Lantrua MG, Valentijn AR, Oostendorp J, Fathers LM, Nijman HW, Drijfhout JW, van de Velde CJ, Melief CJ, van der Burg SH (2009) Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin Cancer Res Off J Am Assoc Cancer Res 15(3):1086–1095. doi:10.​1158/​1078-0432.​CCR-08-2227 CrossRef
32.
go back to reference Burgdorf S, Scholz C, Kautz A, Tampe R, Kurts C (2008) Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation. Nat Immunol 9(5):558–566. doi:10.1038/ni.1601 PubMedCrossRef Burgdorf S, Scholz C, Kautz A, Tampe R, Kurts C (2008) Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation. Nat Immunol 9(5):558–566. doi:10.​1038/​ni.​1601 PubMedCrossRef
33.
go back to reference Singh SK, Stephani J, Schaefer M, Kalay H, Garcia-Vallejo JJ, den Haan J, Saeland E, Sparwasser T, van Kooyk Y (2009) Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation. Mol Immunol 47(2–3):164–174. doi:10.1016/j.molimm.2009.09.026 PubMedCrossRef Singh SK, Stephani J, Schaefer M, Kalay H, Garcia-Vallejo JJ, den Haan J, Saeland E, Sparwasser T, van Kooyk Y (2009) Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation. Mol Immunol 47(2–3):164–174. doi:10.​1016/​j.​molimm.​2009.​09.​026 PubMedCrossRef
35.
go back to reference Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA (1991) CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 174(3):561–569PubMedCrossRef Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA (1991) CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 174(3):561–569PubMedCrossRef
39.
go back to reference Horton H, Thomas EP, Stucky JA, Frank I, Moodie Z, Huang Y, Chiu YL, McElrath MJ, De Rosa SC (2007) Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. J Immunol Methods 323(1):39–54. doi:10.1016/j.jim.2007.03.002 PubMedCrossRef Horton H, Thomas EP, Stucky JA, Frank I, Moodie Z, Huang Y, Chiu YL, McElrath MJ, De Rosa SC (2007) Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. J Immunol Methods 323(1):39–54. doi:10.​1016/​j.​jim.​2007.​03.​002 PubMedCrossRef
40.
go back to reference van der Burg SH, Kalos M, Gouttefangeas C, Janetzki S, Ottensmeier C, Welters MJ, Romero P, Britten CM, Hoos A (2011) Harmonization of immune biomarker assays for clinical studies. Science Trans Med 3(108):108ps44. doi:10.1126/scitranslmed.3002785 CrossRef van der Burg SH, Kalos M, Gouttefangeas C, Janetzki S, Ottensmeier C, Welters MJ, Romero P, Britten CM, Hoos A (2011) Harmonization of immune biomarker assays for clinical studies. Science Trans Med 3(108):108ps44. doi:10.​1126/​scitranslmed.​3002785 CrossRef
41.
go back to reference Marrack P, Kappler J, Mitchell T (1999) Type I interferons keep activated T cells alive. J Exp Med 189(3):521–530PubMedCrossRef Marrack P, Kappler J, Mitchell T (1999) Type I interferons keep activated T cells alive. J Exp Med 189(3):521–530PubMedCrossRef
Metadata
Title
The simultaneous ex vivo detection of low-frequency antigen-specific CD4+ and CD8+ T-cell responses using overlapping peptide pools
Authors
Satwinder Kaur Singh
Maaike Meyering
Tamara H. Ramwadhdoebe
Linda F. M. Stynenbosch
Anke Redeker
Peter J. K. Kuppen
Cornelis J. M. Melief
Marij J. P. Welters
Sjoerd H. van der Burg
Publication date
01-11-2012
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 11/2012
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-012-1251-3

Other articles of this Issue 11/2012

Cancer Immunology, Immunotherapy 11/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine